In a report released today, Jonathan Demchick from Morgan Stanley maintained a Buy rating on Globus Medical (NYSE: GMED), with a price target of $58. The company’s shares opened today at $51.42, close to its 52-week high of $52.56.
Demchick has an average return of 8.7% when recommending Globus Medical.
According to TipRanks.com, Demchick is ranked #1991 out of 4774 analysts.
Currently, the analyst consensus on Globus Medical is Moderate Buy and the average price target is $55.83, representing an 8.6% upside.
In a report released today, Needham also reiterated a Buy rating on the stock with a $58 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.56 and a one-year low of $27.79. Currently, Globus Medical has an average volume of 686K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2018, David Davidar, a Director at GMED sold 70,000 shares for a total of $3,535,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C.
